Physician profile
Michael Evan Williams
NPI 1013743327
$1,243.63
in general payments reported to CMS, 2019-2025
22 companies · $866 in 2025
The $866 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $377 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167 · Travel and Lodging: $76.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.49 |
| Travel and Lodging | $76.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $437.06 | 2024-2025 | Cardiomems |
| Stryker Corporation | $150.00 | 2025 | Flowtriever |
| Abiomed | $86.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.70 | 2025 | |
| Novartis Pharmaceuticals Corporation | $63.30 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.90 | 2025 | Lifevest |
| Biotronik INC. | $52.61 | 2025 | Acticor 7 Vr-T Dx |
| Cardiac Dimensions, INC. | $50.81 | 2025 | |
| Boston Scientific Corporation | $41.08 | 2024-2025 | Watchman Flx, Ekosonic |
| Merck Sharp & Dohme LLC | $28.61 | 2025 | Verquvo, Capvaxive |
| Shockwave Medical, INC | $22.03 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.91 | 2025 | Evkeeza |
| Kestra Medical Technology Services, INC. | $19.66 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $18.96 | 2025 | Camzyos |
| Lilly USA, LLC | $18.35 | 2025 | Zepbound |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17.99 | 2025 | Linq II |
| Amgen INC. | $17.80 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.04 | 2025 | Jardiance |
| Penumbra, INC. | $15.38 | 2024 | Ruby Coil |
| Novo Nordisk INC | $15.03 | 2024 | Rybelsus, Ozempic |
| Terumo Medical Corporation | $14.26 | 2025 | Glidewire, Optitorque, Metacross Otw |
| Astrazeneca Pharmaceuticals LP | $13.18 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.